Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caredx Inc (NQ: CDNA )

29.70 -0.11 (-0.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 443,000
Open 30.10
Bid (Size) 27.96 (1)
Ask (Size) 32.00 (2)
Prev. Close 29.81
Today's Range 29.50 - 30.32
52wk Range 4.800 - 34.84
Shares Outstanding 52,627,165
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire

Performance

YTD
+148.74%
+148.74%
1 Month
-6.60%
-6.60%
3 Month
+106.39%
+106.39%
6 Month
+180.45%
+180.45%
1 Year
+302.99%
+302.99%

More News

Read More
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
From CareDx, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About CareDx
Via Benzinga
Where CareDx Stands With Analysts
Via Benzinga
Decoding 6 Analyst Evaluations For CareDx
Via Benzinga
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
From CareDx, Inc.
Via Business Wire
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
From CareDx, Inc.
Via Business Wire
Navigating 5 Analyst Ratings For CareDx
Via Benzinga
CareDx to Report Second Quarter 2024 Financial Results
From CareDx, Inc.
Via Business Wire
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
From CareDx, Inc.
Via Business Wire
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
From CareDx, Inc.
Via Business Wire
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
From CareDx, Inc.
Via Business Wire
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
Top 3 Health Care Stocks That May Crash In May
Via Benzinga
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
From CareDx, Inc.
Via Business Wire
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
CDNA Stock Earnings: CareDx Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
CareDx Reports First Quarter 2024 Results
From CareDx, Inc.
Via Business Wire
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.